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Abstract
Population protection through vaccination against infectious diseases has been one of the major achievements of public health care. The
recent H1N1 influenza virus pandemic reopened the discussion on the strategic arrangements for vaccination in the face of spreading
infection. Even though vaccination against a pandemic strain is considered to be one of the most effective countermeasures for protect-
ing individuals, the general acceptance of H1N1 influenza vaccination has been low worldwide. The understanding of the potential health
risks of the novel influenza A (H1N1) strain, the distrust of vaccinations and concerns about vaccine safety are the main reasons
reported by the public for not undergoing vaccination. Concern about vaccine safety and distrust of health authorities are the common-
est reasons given for low compliance with vaccination by healthcare workers. Better communication strategies to improve vaccination
acceptance by the general population and by healthcare workers are required.
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Introduction
Vaccinations against infectious diseases are one of the major
achievements of public health care for population protection.
However, notwithstanding the clear effectiveness of the vac-
cination approach, the recent experience with the H1N1
pandemic confirmed that both the general population and
healthcare workers (HCWs) had a low grade of acceptance
of vaccination [1–4].
Most European countries, following the WHO advice
on the need for extensive vaccination of HCWs as a first
priority to protect the essential healthcare infrastructure,
and of the general population, started vaccination cam-
paigns to mitigate the transmission of the influenza pan-
demic [5].
The vaccination rate was very low worldwide and particu-
larly in Europe with the exception of the Netherlands where
a massive campaign was launched with vaccine offered free
of charge even in sports and congress centres [6–8].
The aim of this review is to analyse the reasons behind
this low rate of H1N1 vaccination acceptance in the general
population and in HCWs.
General population
Since the pandemic, an increasing number of studies analysed
the behavioural response of the general population to the
vaccination campaigns trying to identify the barriers to vac-
cine acceptance.
Schwarzinger et al. [9] report a study carried out in
France between 17 November and 25 November 2009. A
total of 2253 adults aged 18–64 years completed an online
survey. Overall, the acceptability of A/H1N1 vaccination was
17.0%. The reason for accepting the vaccination was ‘self-
protection’ in >70% of cases, and around 24% responded
that they consider vaccination as ‘a civic duty’ The main
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2012.03941.x
reasons for not accepting vaccination were concerns about
vaccine safety and fear of vaccine side-effects. The authors
underlined the need for accurate communication of possible
risks by the public health authorities, focused on reassuring
the general population on the vaccine’s safety.
A cross-sectional study, based on a randomly selected
representative sample of the Israeli adult population, showed
similar results—reporting a low uptake of the A/H1N1 vac-
cine (17%) [10]. In this series the low level of acceptance of
vaccination was related to a high level of distrust of the
health institution and health experts, accentuated by uncer-
tainties about the real threat/risk of pandemic and the newly
developed vaccine safety.
Gilles et al. [11] conducted a longitudinal study in Switzer-
land to assess the impact of different factors, including soci-
odemographic factors and trust in institutions, on influenza
vaccination status and perceived efficacy of official recom-
mendations concerning the pandemic. The results of this
study showed that the vaccination rate strongly depends on
trust in medical organizations, confirming that the question
of trust is central to the management of infectious diseases
like influenza.
In fact, there is consistency in the factors affecting vaccina-
tion behaviour across the different studies in different coun-
tries: the degree of fear of novel influenza A (H1N1) and the
beliefs concerning vaccine effectiveness, particularly distrust
of vaccinations, and concerns about vaccine safety [12–15]
(see Table 1).
Healthcare workers
A number of studies have addressed the behavioural
responses to the influenza pandemic in HCWs [2–4,16–26]
(Table 2).
Overall, uncertainty about vaccine side-effects, concern
about vaccine safety and distrust of the health authorities
were the commonest reasons for non-vaccination.
A high compliance with H1N1 vaccination among general
practitioners in the Netherlands was recorded when the
Dutch government urged HCWs to receive vaccination
against the pandemic influenza, financing the costs of the vac-
cine and issuing new guidelines for general practitioner
immunization [22]. These interventions changed the behav-
iour of the Dutch general practitioners from a vaccination
rate of 36% in the 2007–08 influenza season to a vaccination
rate higher than 80% in 2009 [19,23].
The European Respiratory Society-European Society Clini-
cal Microbiology and Infectious Diseases internet survey
showed that the main reasons for vaccination among 834 T
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HCWs who received the H1N1 vaccination were to ‘avoid
virus spread to patients’ and to ‘protect myself’ [4].
These results are mirrored by a study conducted in a pae-
diatric oncology referral centre that showed a high rate of
vaccination among HCWs. In this cohort of HCWs with a
high influenza vaccination rate, realistic assessments of the
potential benefits of vaccination, for both patients and
HCWs, appear to have driven the choice to accept immuni-
zation [25].
Vı´rseda et al. [26] found that in a university hospital in
Spain only 87 of 527 HCWs (16.5%) reported having
received the pandemic influenza (H1N1) 2009 vaccine. Also
in their report the main reasons for acceptance were self-
protection and protection of the patient, whereas the exis-
tence of doubts about vaccine efficacy and fear of adverse
reactions were the main arguments for refusal.
The need to achieve high influenza vaccination rates of
HCWs is a clear CDC indication, and mandatory vaccination
for HCWs has been endorsed by different scientific societies
following the the results of Rakita et al., showing that manda-
tory influenza vaccination campaign successfully increased
vaccination rates with a low rate of request for medical or
religious exemptions [27–29]. However, mandatory vaccina-
tion is a controversial strategy and most of the studies
reported in this review highlight that where public health
authorities have a correct approach to the problem of vacci-
nation and education tools are used, the HCWs’ compliance
is high without any need of making the influenza vaccination
a mandatory condition.
Conclusions
The low acceptance of H1N1 vaccination was probably the
result of a mixture of public scepticism, distrust of the health
authorities’ indications and misinformation being raised by a
growing anti-vaccination lobby, who actively contested both
the need and safety of the pandemic influenza vaccine across
Europe.
However, it must be also take into account that three
Cochrane reviews questioned the need and the advantages
of seasonal influenza vaccination in healthy adults, in the
elderly and in HCWs [30–32].
All of these meta-analyses were performed by the same
group, who reported that not only was the reliable evidence
on influenza vaccines thin but it also indicated the possible
widespread manipulation of conclusions and spurious fame of
the studies analysed.
Notwithstanding these conclusions, the European Respira-
tory Society and European Society Clinical Microbiology and
Infectious Diseases guidelines [33] indicate that influenza vac-
cine should be given yearly to persons at increased risk of
complications due to influenza with fairly strong evidence
(A2). Moreover, the guidelines suggest, with moderate evi-
dence (B2), a yearly vaccination of healthcare personnel,
especially in settings where elderly persons or other high-
risk groups are treated.
In conclusion, vaccines are the best option we have for
controlling infectious diseases but we need to improve the
communication between Health Authorities, Scientific Socie-
ties, HCWs and the general population with simple, clear,
honest and straightforward messages.
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